Rifei Liang
Biographic Data
| ID | 5544609 |
|---|---|
| NAME | Rifei Liang |
| GIVEN NAMES | Rifei |
| FAMILY NAME | Liang |
| SIGNATURE | LIANG R |
| AFFILIATIONS | University of Colorado Cancer Center Aurora, CO |
| ORCID | 0000-0003-3260-7213 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2023 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
High-Cost Cancer Drug Use in Medicare Advantage and Traditional Medicare
In this cohort study, high-cost drugs were more commonly prescribed among patients enrolled in TM and diagnosed with CRC. A similar pattern was not observed for patients with NSCLC, perhaps because clinical evidence suggests survival benefits to be associated only with certain drugs, all of which are expensive. Nonetheless, MA was modestly associated with reduced high-cost drug utilization and may reduce overall treatment costs
Treatment Disparities in Radiation and Hormone Therapy Among Women Covered by Medicaid vs Private Insurance in Cancer Registry and Claims Data
Among women with breast cancer covered by Medicaid vs private insurance, cancer treatment disparities may be overestimated if based solely on cancer registry data
Building Data Infrastructure for Disease-Focused Health Economics Research
BACKGROUND: Data infrastructure for cancer research is centered on registries that are often augmented with payer or hospital discharge databases, but these linkages are limited. A recent alternative in some states is to augment registry data with All-Payer Claims Databases (APCDs). These linkages capture patient-centered economic outcomes, including those driven by insurance and influence health equity, and can serve as a prototype for health ec…
No prominent works on this page.
Treatment Disparities in Radiation and Hormone Therapy Among Women Covered by Medicaid vs Private Insurance in Cancer Registry and Claims Data
Among women with breast cancer covered by Medicaid vs private insurance, cancer treatment disparities may be overestimated if based solely on cancer registry data
Building Data Infrastructure for Disease-Focused Health Economics Research
BACKGROUND: Data infrastructure for cancer research is centered on registries that are often augmented with payer or hospital discharge databases, but these linkages are limited. A recent alternative in some states is to augment registry data with All-Payer Claims Databases (APCDs). These linkages capture patient-centered economic outcomes, including those driven by insurance and influence health equity, and can serve as a prototype for health ec…
High-Cost Cancer Drug Use in Medicare Advantage and Traditional Medicare
In this cohort study, high-cost drugs were more commonly prescribed among patients enrolled in TM and diagnosed with CRC. A similar pattern was not observed for patients with NSCLC, perhaps because clinical evidence suggests survival benefits to be associated only with certain drugs, all of which are expensive. Nonetheless, MA was modestly associated with reduced high-cost drug utilization and may reduce overall treatment costs
Economic and Financial Impacts of Cancer (3 works) · Medicine (3 works) · Cancer (2 works) · Cancer registry (2 works) · Cohort (2 works) · Family medicine (2 works) · Global Cancer Incidence and Screening (2 works) · Health care (2 works) · Healthcare Policy and Management (2 works) · Internal Medicine (2 works)